PET and PET/CT in Treatment Planning
- Author(s)
- MacManus, M; Everitt, S; Hicks, RJ;
- Journal Title
- In: Jeremić, B. (ed) Advances in Radiation Oncology in Lung Cancer, Third Edition, Volume I
- Publication Type
- Book section
- Abstract
- Positron emission tomography/computed tomography (PET/CT) imaging now plays a fundamental role in treatment planning for patients with lung cancer, particularly for those who are candidates for potentially curative radiation therapy (RT) (Akhurst et al. 2015; De Ruysscher et al. 2010). 18F-Fluorodeoxyglucose (18F-FDG) remains the most widely used PET radiopharmaceutical in oncology and FDG-PET has proven to be the most accurate whole-body imaging modality for staging lung cancer since almost all types are highly metabolically active. This results in high contrast between FDG uptake in tumor and most surrounding normal tissues (apart from the central nervous system and urinary tract) facilitating lesion detection throughout the body including primary, nodal, and metastatic sites (MacManus et al. 2001). With dissemination of hybrid PET/CT scanners, the information provided by PET is complemented by detailed structural information from a contemporaneous CT component, but further complementary imaging using specialized CT protocols or magnetic resonance imaging (MRI) can provide additional correlative information to improve diagnostic certainty. Serial imaging provides unique insights in the evolution of cancers both structurally and metabolically in response to treatment and PET/CT has thus become an important diagnostic tool in therapeutic response assessment and restaging of suspected relapse.
- Publisher
- Springer International Publishing
- Department(s)
- Radiation Oncology; Cancer Imaging
- Publisher's Version
- https://doi.org/10.1007/174_2022_308
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-08-20 06:17:32
Last Modified: 2024-08-20 06:56:39